Vor Biopharma

goal

Pharma

RemeGen's telitacicept result sets up IgAN submission in China

For the second time in two weeks, RemeGen and Vor Bio have reported a phase 3 win for telitacicept, this time in IgA nephropathy.

Kevin Dunleavy Aug 27, 2025 11:13am

On target clinical trial success bullseye score

RemeGen's telitacicept meets the mark in ph. 3 Sjögren's study

Aug 13, 2025 10:03am

Graphic image of a man climbing up a latter in front of a beige background with clouds and a blue splotch of sky

Ex-Sarepta exec lands at Vor Bio as commercial chief

Aug 7, 2025 10:13am

Conceptual illustration of layoffs featuring rows of translucent human figures overlaid with large blue scissors symbolizing

Fierce Biotech

Biopharma layoffs hit 4-year monthly high in May

Jul 8, 2025 2:26pm

Asia

RemeGen, Harbour, Datroway—Fierce Pharma Asia

Jun 27, 2025 8:37am

A one dollar bill sitting next to a declining stock graph

Vor Bio's surprise $4B revival deal splits investor reactions

Jun 26, 2025 10:55am